Haro Hartounian, Ph.D. Honored by ROI-NJ in 2021 List of ROI Influencers for Health Care
Dr. Haro Hartounian, SVP and General Manager of BioCentriq, was recognized as a Sector Star.
Read moreDr. Haro Hartounian, SVP and General Manager of BioCentriq, was recognized as a Sector Star.
Read moreTerumo Blood and Cell Technologies (Terumo) and BioCentriq announce the formation of a strategic collaboration.
Read moreNJII announces partnership with McKinsey & Company in the launch of a new center to advance operations and manufacturing excellence in cell and gene therapy (CGT).
Read moreCaroGen Corporation partners with BioCentriq™ as their partner for clinical manufacturing to support Phase 1 clinical trial. Learn more.
Read moreBioCentriq, a cell and gene therapy development and manufacturing center, is pleased to announce that Shannon Eaker of Cytiva has joined its advisory committee. Shannon earned his Ph.D. from the University of Tennessee, Knoxville in …
Read moreNEWARK, NJ, March 23, 2021 – BioCentriq™, the New Jersey Innovation Institute’s cell and gene therapy development and manufacturing center, announces its partnership with Kytopen, a Cambridge based startup spun out of Massachusetts Institute of Technology …
Read moreUnder this partnership, experts from BioCentriq and Tevogen Bio will collaborate at BioCentriq’s state-of-the art GMP facilities to produce Tevogen’s proprietary COVID-19 targeted T cells. The teams will utilize the processes and technology required to …
Read moreFOR IMMEDIATE RELEASE: Virtual ribbon cutting and tour featured remarks from New Jersey Governor Phil Murphy, FDA’s Peter Marks, as well as panel discussions with industry leaders from ARM, NIIMBL, Century Therapeutics, BioNJ, NJEDA, NJIT …
Read moreIf your start-up company has developed a biological product and is planning to file an investigational new drug (IND) application with the FDA or register the product with another federal agency, and you don’t have …
Read moreThe New Jersey Innovation Institute (NJII) and Choose New Jersey will be hosting a virtual ribbon cutting, tour and panel discussions to mark the opening of BioCentriq™ on Thursday, October 29 at 2:30pm. RSVP to …
Read moreA research report published just yesterday by Allied Market research affirms that the global viral vectors and plasmid DNA manufacturing market generated $918.37 million in 2019, and is projected to reach $4.97 billion by 2027, …
Read moreThe New Jersey Innovation Institute’s Biopharma Division, which includes BioCentriq, its cell and gene therapy development and manufacturing center, has welcomed Beth Thompson-Webb to its advisory committee. Thompson-Webb has more than two decades of experience in life sciences …
Read more